Literature DB >> 17690125

Effects of systemic steroids in patients with severe community-acquired pneumonia.

C Garcia-Vidal1, E Calbo, V Pascual, C Ferrer, S Quintana, J Garau.   

Abstract

The benefit of systemic steroids as adjunctive treatment in patients with severe community-acquired pneumonia (CAP) remains unclear. The present study aimed to evaluate the impact of corticosteroid treatment on mortality in patients with severe CAP. A retrospective, observational study of a cohort of patients hospitalised with severe CAP, classes IV and V of the Prognostic Severity Index score, was carried out. Information on epidemiological, clinical and laboratory data, and 30-day mortality was collected from medical charts. Of the 308 patients evaluated, 238 (77%) were treated with standard antimicrobial therapy and 70 (23%) received both antibiotics and systemic steroids. Clinical characteristics were similar between steroid and nonsteroid groups, except in the prevalence of male sex and the presence of chronic obstructive pulmonary disease. Systemic steroids were independently associated with a decreased mortality (odds ratio 0.287; 95% confidence interval 0.113-0.732), while severity of CAP (2.923; 1.262-6.770) was the only independent factor associated with increased mortality. Mortality decreased in the patients with severe CAP who received simultaneous administration of systemic steroids along with antibiotic treatment. Severity of community-acquired pneumonia remains the most important risk factor associated with increased mortality.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690125     DOI: 10.1183/09031936.00027607

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  42 in total

Review 1.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Statins for community-acquired pneumonia: current state of the science.

Authors:  D Viasus; C Garcia-Vidal; F Gudiol; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-27       Impact factor: 3.267

3.  Relation between chronic obstructive pulmonary disease and antibiotics.

Authors:  Salvador Sialer; Liapikou Adamantia; Mónica Guerrero; Antoni Torres
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

4.  Adjuvant therapies in critical care: steroids to treat infectious diseases.

Authors:  José Manuel Pereira; Thiago Lisboa; José-Artur Paiva
Journal:  Intensive Care Med       Date:  2017-12-11       Impact factor: 17.440

5.  Adjunct corticosteroids in children hospitalized with community-acquired pneumonia.

Authors:  Anna K Weiss; Matthew Hall; Grace E Lee; Matthew P Kronman; Seth Sheffler-Collins; Samir S Shah
Journal:  Pediatrics       Date:  2011-01-10       Impact factor: 7.124

6.  Community-acquired pneumonia in patients with chronic obstructive pulmonary disease.

Authors:  Aykut Cilli
Journal:  Curr Infect Dis Rep       Date:  2015-01       Impact factor: 3.725

7.  Benefit of adjunct corticosteroids for community-acquired pneumonia in diabetic patients.

Authors:  Milica Popovic; Claudine A Blum; Nicole Nigro; Beat Mueller; Philipp Schuetz; Mirjam Christ-Crain
Journal:  Diabetologia       Date:  2016-09-10       Impact factor: 10.122

8.  Pneumonia in elderly patients with chronic obstructive pulmonary disease.

Authors:  Pierre Ernst; Samy Suissa
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

9.  Bacteraemic pneumococcal pneumonia in COPD patients: better outcomes than expected.

Authors:  E Calbo; E Valdés; A Ochoa de Echagüen; A Fleites; L Molinos; M Xercavins; N Freixas; M Rodríguez-Carballeira; J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-10       Impact factor: 3.267

10.  Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough.

Authors:  Alejandro Rodriguez; Thiago Lisboa; Stijn Blot; Ignacio Martin-Loeches; Jorge Solé-Violan; Diego De Mendoza; Jordi Rello
Journal:  Intensive Care Med       Date:  2008-12-10       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.